Topoisomerase-I inhibitors for human malignant glioma: Differential modulation of p53, p21, bax and bcl-2 expression and of CD95-mediated apoptosis by camptothecin and β-lapachone

International Journal of Cancer

Volumn 73, Issue 5, 1997, Pages 707-714

  Weller, Michael ^a   Winter, Stephan ^a   Schmidt, Christine ^a   Esser, Peter ^b   Fontana, Adriano ^c   Dichgans, Johannes ^a   Groscurth, Peter ^c  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BAX PROTEIN, HUMAN; BETA LAPACHONE; BETA-LAPACHONE; CAMPTOTHECIN; CDKN1A PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; DNA TOPOISOMERASE; FAS ANTIGEN; NAPHTHOQUINONE; ONCOPROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL DIVISION; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; GLIOMA; HUMAN; IMMUNOTHERAPY; METABOLISM; PATHOLOGY;

ANTIGENS, CD95; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CAMPTOTHECIN; CELL CYCLE PROTEINS; CELL DIVISION; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA TOPOISOMERASES, TYPE I; GLIOMA; HUMANS; IMMUNOTHERAPY; NAPHTHOQUINONES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031588345     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19971127)73:5<707::AID-IJC16>3.0.CO;2-2     Document Type: Article

References (21)

1. BOORSTEN, R.J. and PARDEE, A.B., β-lapachone greatly enhances MMS lethality to human fibroblasts. Biochem. biophys. Res. Commun., 118, 828-834 (1984).
2. BOOTHMAN, D.A., WANG, M., SCHEA, R.A., BURROWS, H.L., STRICKFADEN, S. and OWENS, J.K., Post-treatment exposure to camptothecin enhances the lethal effects of X-rays on radioresistant human malignant melanoma cells. Int. J. Radiat. Oncol. Biol. Phys., 24, 939-948 (1992).
3. HARE, C.B., ELION, G.B., HOUGHTON, P., HOUCHTON, J., KEIR, S., MARCELLI, S.L., BIGNER, D.D. and FRIEDMAN, H.S., Treatment of central nervous system xenografts with CPT-11. Proc. Amer. Ass. Cancer Res., 37, 2959 (1996).
4. LEITHÄUSER, F., DHEIN, J., MECHTERSHEIMER, G., KORETZ, K., BRÜDERLEIN, S., HENNE, C., SCHMIDT, A., DEBATIN, K.M., KRAMMER, P.H. and MÖLLER, P., Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab. Invest., 69, 415-429 (1993).
5. LI, C.J., AVERBOUKH, L. and PARDEE, A.B., β-lapachone, a novel DNA-topoisomerase inhibitor with a mode of action different from camptothecin. J. biol. Chem., 268, 22463-22468 (1993).
6. LI, C.J., WANG, C. and PARDEE, A. B., Induction of apoptosis by β-lapachone in human prostate cancer cells. Cancer Res., 55, 3712-3715 (1995).
7. MATSUMOTO, Y., FUJIWARA, T., HONJO, Y., SASAOKA, N., TSUCHIDA, T. and NAGAO, S., Quantitative analysis of DNA-topoisomerase-1 activity in human and rat glioma: characterization and mechanism of resistance to anti-topoisomerase chemical, camptothecin-11. J. surg. Oncol., 53, 97-103 (1993).
8. MORRIS, E.J. and GELLER, H.M., Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase-1: evidence for cell-cycle-independent toxicity. J. Cell Biol., 134, 757-770 (1996).
9. OGASAWARA, J., WATANABE-FUKUNAGA, R., ADACHI, M., MATSUZAWA, A., KASUGAI, T., KITAMURA, Y., ITOH, N., SUDA, T. and NAGATA, S., Lethal effect of the anti-Fas antibody in mice. Nature (Lond.), 364, 806-809 (1993).
10. PLANCHON, S.M., WUERZBERGER, S., FRYDMAN, B., WITIAK, D.T., HUTSON, P., CHURCH, D.R., WILDING, G. and BOOTHMAN, D.A., β-lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate-cancer cells: a p53-independent response. Cancer Res., 55, 3706-3711 (1995).
11. POTMESIL, M., VARDEMAN, D., KOZIELSKI, A.J., MENDOZA, J., STEHLIN, J.S. and GIOVANELLA, B.C., Growth inhibition of human cancer metastases by camptothecins in newly developed xenograft models. Cancer Res., 55, 5637-5641 (1995).
12. RENSING-EHL, A., FREI, K., FLURY, R., MATIBA, B., MARIANI, S.M., WELLER, M., AEBISCHER, P., KRAMMER, P.H. and FONTANA, A., Loco-regional Fas/APO-1(CD95) ligand-mediated tumor-cell killing in vivo. Europ. J. Immunol., 25, 2253-2258 (1995).
13. ROTH, W., FONTANA, A., TREPEL, M., DICHGANS, J., REED, J.C. and WELLER, M., Immunochemotherapy of malignant glioma: synergistic activity of CD95 ligand and chemotherapeutics. Cancer Immunol. Immunother., 48, 55-63 (1997).
14. TACHIBANA, O., NAKAZAWA, H., LAMPE, J., WATANABE, K., KLEIHUES, P. and OHGAKI, H., Expression of Fas/APO-1 during the progression of astrocytomas. Cancer Res., 55, 5528-5530 (1995).
15. VAN MEIR, E.G., KIKUCHI, T., TADA, T., LI, H., DISERENS, A.C., WOJCIK, B.E., HUANG, H.J.S., FRIEDMANN, T., DE TRIBOLET, N. and CAVENEE, W.K., Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res., 54, 649-652 (1994).
16. WALTON, M.I., WHYSONG, D., O'CONNOR, P.M., HOCKENBERY, D., KORSMEYER, S.J. and KOHN, K.W., Constitutive expression of human bcl-2 modulates nitrogen mustard- and camptothecin-induced apoptosis. Cancer Res., 53, 1853-1861 (1993).
17. WEINGART, J.D., THOMPSON, R.C., TYLER, B., COLVIN, O.M. and BREM, H., Local delivery of the topoisomerase-I inhibitor camptothecin sodium prolongs survival in the rat intracranial 9L gliosarcoma model. Int. J. Cancer. 62, 605-609 (1995).
18. WELLER, M., FREI, F., GROSCURTH, P., KRAMMER, P.H., YONEKAWA, Y. and FONTANA, A., Anti-Fas/APO-1-antibody-mediated apoptosis of cultured human malignant glioma cells. Induction and modulation of sensitivity by cytokines. J. clin. Invest., 94, 954-964 (1994).
19. WELLER, M., MALIPIERO, U., RENSING-EHL, A. BARR, P. and FONTANA, A., Fas/APO-1 gene transfer for human malignant glioma. Cancer Res., 55, 2936-2944 (1995a).
20. WELLER, M., MALIPIERO, U.V., AGUZZI, A., REED, J.C. and FONTANA, A., Proto-oncogene bcl-2 gene transfer abrogates Fas/APO-1-antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J. clin. Invest., 95, 2633-2643 (1995b).
21. WELLER, M., SCHMIDT, C., ROTH, W. and DICHGANS, J., Chemotherapy of human malignant glioma: prevention of efficacy by dexamethasone? Neurology, 48, 1704-1709 (1997).